Medpace Logo

For Immediate Release: June 7, 2018

Julie Hopkins
513-579-9911 x 12627

Medpace Medical Director to Chair Session at the DIA 2018 Annual Meeting

“Novel Approaches for Accessing the CNS: Nonclinical and Clinical Challenges”

CINCINNATI, OH — (June 7, 2018) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that Richard Scheyer, MD, Vice President of Medical Affairs at Medpace, will be presenting at the upcoming DIA 2018 Annual Meeting during the following session:

#207: Novel Approaches for Accessing the CNS: Nonclinical and Clinical Challenges
When: Tuesday, June 26 8:00am – 9:00am
Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-18-560-L04-P; CME 1.00; IACET 1.00; RN 1.00

This session will highlight new approaches in CNS-targeted therapeutics. These approaches to identify and develop therapies able to reach the CNS and address specific genetic perturbations are being pioneered in rare disease, and require disciplined approaches to study designs and execution. Attendees will learn to:

  • Identify and address hurdles in pre-clinical evaluation, identification of appropriate patients, and administration of treatments crossing or bypassing the blood brain barrier
  • Design studies for advanced treatment modalities, with focus on CNS therapeutics.
  • Confirm target engagement and biologic impact.

You can view the session in its entirety by viewing the program agenda.

About Richard Scheyer, MD

Dr. Richard Scheyer is VP Medical Affairs at Medpace. Prior to Medpace, he led Experimental Medicine, BM, and PGx functions at Daiichi Sankyo. He served in leadership roles at Sanofi-Aventis and CMO at Neurotrope Bioscience. Dr. Scheyer received his BS Physics from Stanford, MD from SUNY Upstate, and completed residency and fellowship at Yale before joining the Neurology faculty. He served on the FNIH Biomarkers Consortium and the Board of the SAE Consortium.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,600 people across 36 countries.